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Proton pump inhibitor (PPI) use leads to hypergastrinaemia, which has been associated with gastrointestinal neoplasia. We evaluated
the association between PPI use and risk of gastric cancer using population-based health-care registers in North Jutland, Denmark,
during 1990–2003. We compared incidence rates among new users of PPI (n¼18790) or histamine-2-antagonists (H2RAs)
(n¼17478) and non-users of either drug. Poisson regression analysis was used to estimate incidence rate ratios (IRRs) adjusted for
multiple confounders. We incorporated a 1-year lag time to address potential reverse causation. We identified 109 gastric cancer
cases among PPI users and 52 cases among H2RA users. After incorporating the 1-year lag time, we observed IRRs for gastric cancer
of 1.2 (95% CI: 0.8–2.0) among PPI users and 1.2 (95% CI: 0.8–1.8) among H2RA users compared with non-users. These estimates
are in contrast to significant overall IRRs of 9.0 and 2.8, respectively, without the lag time. In lag time analyses, increased IRRs were
observed among PPI users with the largest number of prescriptions or the longest follow-up compared with H2RA users or non-
users. Although our results point to a major influence of reverse causation and confounding by indication on the association between
PPI use and gastric cancer incidence, the finding of increased incidence among PPI users with most prescriptions and longest follow-up
warrants further investigation.
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There has been some concern about the long-term safety of
proton pump inhibitors (PPIs). The profound reduction in gastric
acid secretion induced by PPIs leads to increased secretion of
gastrin, and most PPI users have moderate hypergastrinaemia
(Lamberts et al, 1988; Klinkenberg-Knol et al, 1994). Gastrin has
trophic effects on the gastrointestinal mucosa, and hypergastri-
naemia has been associated with an increased risk of gastric
carcinoids, and gastric and colonic carcinomas (Havu, 1986; Laine
et al, 2000; Gillen and McColl, 2001; Waldum et al, 2005; Kuipers,
2006), although recent results for PPI use and colorectal cancer
risk are reassuring (Robertson et al, 2007; Yang et al, 2007; van
Soest et al, 2008). Hyperplasia of enterochromaffin-like cells has
been seen in long-term PPI users (Lamberts et al, 1993; Eissele
et al, 1997; Klinkenberg-Knol et al, 2000); and in patients with
Helicobacter pylori (H. Pylori) infection, long-term PPI use has
been associated with an increased incidence of atrophic gastritis
(Kuipers et al, 1996), a precursor of gastric adenocarcinoma
(Uemura et al, 2001; Ye and Nyren, 2003).
Few epidemiological studies have evaluated the association
between PPI use and gastric cancer. Two studies based on UK
populations reported an increased risk of gastric cancer among
users of PPI that was attributed to probable reverse causation or
confounding by indication (Bateman et al, 2003; Garcia Rodriguez
et al, 2006). Given the widespread use of PPI and the unresolved
questions about their carcinogenic potential, we examined the
association between PPI use and the risk of gastric cancer in a large
population-based cohort of Danish PPI users.
MATERIALS AND METHODS
We conducted this population-based cohort study within North
Jutland County, Denmark (B500000 inhabitants) in 1990–2003.
The Danish National Health-care System provides all Danish
citizens with unrestricted access to tax-supported public medical
services and reimbursement of most prescribed drugs, including
PPIs and histamine-2-antagonists (H2RAs). All medical services
are registered to individual patients by use of a civil registry
number assigned to all Danish citizens, which encodes gender and
date of birth. Its use allows identification of complete prescription
and hospitalisation histories for each individual.
Using the Danish Civil Registration System that has provided
information on vital status and residence for the entire population
since 1968, we identified all individuals aged 40–84 years during
the study period and resident in North Jutland County on
1 January 1989. We excluded all individuals with a history of
cancer (except non-melanoma skin cancer) before study entry
(1990 or age 40) by linkage to the Danish Cancer Registry, which
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ment of cancers (Storm et al, 1997). In an attempt to include only
new users of acid-suppressive drugs (Ray, 2003), all individuals
who filed prescriptions for PPI or H2RA during 1989 or before
turning 40 during the study period (i.e., before becoming eligible
for analysis) were excluded from the study population. The final
study population comprised of 280872 individuals.
In North Jutland County, prescription data from all pharmacies
are electronically transferred to a research database at Aarhus
University Hospital, initiated in 1989 (Gaist et al, 1997). The
database holds key information on all prescriptions dispensed for
reimbursable drugs, including the type and amount of drug
(according to the ATC classification system), date of dispensing at
the pharmacy and the individual’s civil registry number. Use of
PPI (ATC code A02BC) was defined as filing X2 PPI prescriptions
during the study period and H2RA use similarly (ATC code
A02BA). Non-use of drug was defined as less than two prescrip-
tions for either drug; mixed use (X2 prescriptions of both PPI and
H2RA) was not evaluated. We were not able to obtain valid
information on indication for use of PPI and H2RA as indication
for use was not recorded in the prescription database.
From the database, we identified patients who had undergone
H. Pylori eradication therapy, namely those who within the study
period filed simultaneous prescriptions for any two of the three
antibiotics (amoxicillin, clarithromycin and metronidazole; ATC
codes: J01CA04, J01FA09 and P01AB01) used in triple therapy
(Malfertheiner et al, 2006). In addition, we obtained prescription
data for non-steroidal anti-inflammatory drugs (NSAIDs) (ATC
codes: M01A, N02BA01, N02BA51 and B01AC06).
All patients who had undergone gastroscopy (Danish Classifi-
cation of Surgical Procedures and Therapies (Danish Board of
Health, 1989, 1995) codes: 91010 (1977–1995); UJD02, UJD05
(1996–2005)) in North Jutland County were identified from the
County Hospital Discharge Registry containing information on all
non-psychiatric hospital admissions (since 1977) and out-patient
visits (since 1995) (Andersen et al, 1999). If the exact date of
gastroscopy was not available, we used the first day of admission.
To exclude registrations of gastroscopy used in the diagnosis of
gastric cancer cases, we excluded examinations performed p1 year
preceding censoring event, by adding 1 year to all gastroscopy
dates.
Proxy measures of smoking and alcohol abuse were assessed
from information in the hospital and prescription registers. For
heavy smoking individuals, we obtained information on first
admission for chronic obstructive pulmonary disorder (COPD)
(ICD-8: 490–492; ICD-10: J40–44). For heavy alcohol use
individuals, we identified the date of first recorded prescription
for drugs used to treat alcohol addiction (disulfiram, acamprosate
and naltrexone) (ATC codes: N07BB01, 03, 04; V03AA01, 02)
or admission for alcohol-related diseases, including psychiatric
and neurological conditions, gastrointestinal disease and alcohol
poisoning (ICD-8: 291, 303, 57109, 57110, 57710, 979, 980;
ICD-10: F10, G312, G621, G721, I426, K292, K70, K860, R780,
T51, Z721).
Information on first primary diagnoses of gastric and other
cancers was obtained from the Danish Cancer Registry. Gastric
cancer cases were identified by the topographical head category
151 according to a modified Danish version of the International
Classification of Diseases, seventh revision (ICD-7). We were not
able to meaningfully evaluate associations by gastric subsite, as
more than 40% of cancer cases were classified as unspecified
gastric cancers (ICD-7: 151.0).
Subjects entered the study population on 1 January 1990 or age
40, whichever occurred latest, and were censored on first occurring
date of primary gastric cancer, other primary cancer (except non-
melanoma skin cancer), age 85, death, migration from North
Jutland County, 31 December 2003 or, for PPI or H2RA users, at
second prescription for the other agent (i.e., mixed use).
The person time of the study subjects was broken down
according to PPI or H2RA use in exposed time (X2 prescriptions)
(PPI or H2RA use) and unexposed time (o2 prescriptions) (non-
use of both PPI and H2RA). Person time between first and second
PPI or H2RA prescription was treated as unexposed. Person time
for PPI or H2RA use was further categorized into four exposure
periods based on duration of follow-up since the second
prescription (o1, 1, 2–4 and 5þ years). Person time for PPI or
H2RA use was also categorized according to the number of
prescriptions filled (2–4, 5–14 and 15þ prescriptions).
Statistical analysis
Log-linear Poisson regression analysis was used to compute
incidence rate ratios (IRRs) for gastric cancer among PPI and
H2RA users compared with non-users. To minimise the potential
influence of protopathic bias (reverse causation) on PPI use and
gastric cancer, we incorporated a 1-year lag time in the main
analyses, by subtracting 1 year from the date of gastric cancer
diagnosis or censoring dates, except for age and shift of treatment.
In an attempt to account for unmeasured confounding factors, we
also computed IRR estimates in direct comparisons of PPI and
H2RA users in equivalent strata of prescription frequency and
length of follow up.
All analyses were adjusted for calendar period (1990–1996,
1997–2003), gender, age (40–49, 50–59, 60–69 and 70–85 years),
history of H. pylori eradication therapy (yes/no), gastroscopy (X1
year before gastric cancer diagnosis or other censoring event) (yes/
no), COPD (yes/no), alcohol-related admission or therapy (yes/no)
and ever use of NSAIDs (0–1, 2þ prescriptions). The proxy
variables for heavy smoking and alcohol abuse had no appreciable
effect on the risk estimates and were therefore dropped from the
final models. Subjects were allowed to change between categories
of covariates and exposure variables over time. Within each
categorical level all variables were treated as time independent.
The statistical analyses were performed in SAS 9.1.
RESULTS
We identified 18790 new users of PPI with less than two earlier
recorded prescriptions for H2RA and 17478 new users of H2RA
with less than two earlier recorded PPI prescriptions. After
incorporation of the 1-year lag time, 15065 new PPI users and
16176 new H2RA users remained. Characteristics of the groups are
presented in Table 1. PPI users were slightly older than H2RA
users and had slightly higher use of NSAIDs. Of PPI users, 13 and
4% of H2RA users, had undergone H. pylori eradication therapy. A
record of gastroscopy (X1 year before censoring events) was
found among 47% of PPI users, 33% of H2RA users (Table 1) and
11% of the total study population (results not shown). Use of
PPI increased markedly during the study period. Omeprazole
accounted for the majority of PPI use, whereas cimetidine was
the most frequently prescribed H2RA. A similar distribution of
characteristics was found in the lagged study population (data not
shown).
Overall, PPI users accrued 66630 person-years with a mean
follow-up of 3.5 years (range: 0–13.8 years), and H2RA users
accrued 90904 person-years (mean: 5.2, range: 0–13.9 years). After
incorporating the 1-year lag time, the corresponding person-years
were 51854 (mean: 3.4, range: 0–12.8 years) among PPI users and
81256 (mean: 5.0, range: 0–12.9 years) among H2RA users. In the
lag time analysis, 1111 PPI users and 5673 H2RA users were
censored because of use of the other agent during follow up. We
observed 109 cases of gastric cancer among PPI users and 52 cases
among H2RA users. The overall (not taking lag time into account)
IRR of gastric cancer was 9.0 (95% CI: 6.9–11.7) among PPI users
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users (o2 prescriptions) of both PPI and H2RA (data not shown).
Results of the lag time analysis are presented in Table 2. The IRR
of gastric cancer was 1.2 (95% CI: 0.8–2.0; based on 24 exposed
cases) among PPI users and 1.2 (95% CI: 0.8–1.8; 30 exposed
cases) among H2RA users, compared with non-users. Comparison
between PPI users and H2RA users yielded an overall IRR for PPI
use of 1.3 (95% CI: 0.7–2.3) Stratifying PPI users by duration of
follow-up yielded increased IRRs for gastric cancer with less than
1 year of follow-up compared with non-users (IRR 2.3, 95% CI:
1.2–4.3) or H2RA users (2.4 95% CI: 0.7–8.0). In intermediate
follow-up periods (1–4 years), the corresponding IRRs were below
unity in both comparisons, whereas PPI users with 5 or more years
of follow-up experienced an IRR of 2.3 (95% CI: 1.2–4.3) when
compared with non-users and 1.8 (95% CI: 0.6–5.0) when
compared with H2RA users.
Stratification showed increasing IRRs with increasing number of
prescriptions when compared with non-use of acid-suppressing
drugs, from 0.8 (95% CI: 0.4–1.6) with 2–4 PPI prescriptions
to 2.1 (95% CI: 1.0–4.7) with 15 or more prescriptions. When
compared with H2RA users with equivalent number of prescrip-
tions, however, no clear pattern emerged and the IRR associated
with 15 or more prescriptions was 1.4 (95% CI: 0.5–4.3).
Stratification of PPI users in the lag time analysis by history/no
history of H. pylori eradication yielded IRRs of 3.3 (n¼7; 95% CI:
Table 2 Adjusted rate ratios for gastric cancer for exclusive users of PPIs
and H2RAs compared with non-users of both PPI and H2RA, and for PPI
users compared with H2RA users
Lag time¼1 Year
a
Person-years Gastric cancers IRR (95% CI)
b
Unexposed 2345905 519 reference
PPI vs Unexposed
2+ Prescriptions 51854 24 1.2 (0.8–2.0)
Years of follow-up
o1 13316 10 2.3 (1.2–4.3)
1 10391 3 0.8 (0.2–2.4)
2–4 19363 4 0.5 (0.2–1.4)
5+ 8783 7 2.3 (1.2–4.3)
No. of prescriptions
2–4 30588 8 0.8 (0.4–1.6)
5–14 13851 9 1.6 (0.8–3.3)
15+ 7415 7 2.1 (1.0–4.7)
H2RA vs Unexposed
2+ Prescriptions 81256 30 1.2 (0.8–1.8)
Years of follow-up
o1 14847 5 1.2 (0.5–2.8)
1 12821 10 2.6 (1.4–4.9)
2–4 28925 6 0.7 (0.3–1.5)
5+ 24663 9 1.1 (0.5–2.8)
No. of prescriptions
2–4 43060 9 0.8 (0.4–1.5)
5–14 24213 13 1.7 (0.9–2.9)
15+ 13984 8 1.6 (0.8–3.2)
PPI vs H2RA
2+ Prescriptions 1.3 (0.7–2.3)
Years of follow-up
o1 2.4 (0.7–8.0)
1 0.7 (0.2–3.0)
2–4 0.8 (0.2–3.3)
5+ 1.8 (0.6–5.0)
No. of prescriptions
2–4 1.1 (0.4–3.2)
5–14 1.7 (0.7–4.5)
15+ 1.4 (0.5–4.3)
Abbreviations: H2RA¼histamine-2-antagonist; IRR¼incidence rate ratio; PPI¼pro-
ton pump inhibitor. North Jutland County, Denmark (1990–2003).
a1y e a r
subtracted from diagnosis and censoring dates (except age and shift of treatment).
bAdjusted for: age, gender, calendar period, gastroscopy (X1 year before censoring
events), use of NSAIDs and H. pylori eradication.
Table 1 Characteristics of exclusive users of PPIs and H2RAs
PPI H2RA
n % n %
Total
Persons 18790 100 17478 100
Females 10026 53 9463 54
Males 8764 47 8015 46
Age
40–49 3805 20 4052 23
50–59 4663 25 4262 24
60–69 4328 23 4130 24
70+ 5994 32 5034 29
Mean 62 61
Calendar year
1990–1991 353 2 3603 21
1992–1993 1253 7 4927 28
1994–1995 2141 11 3538 20
1996–1997 3001 16 2220 13
1998–1999 3597 19 1510 9
2000–2001 3834 20 944 5
2002–2003 4611 25 736 4
Number of prescriptions
2–4 9155 49 7970 46
5–14 5624 30 5152 29
15+ 4011 21 4356 25
Other medical treatment or procedures
NSAID use 14403 77 11761 67
H. pylori eradication
a 2371 13 694 4
Gastroscopy
b 8861 47 5768 33
Lifestyle factors
c
COPD 1034 6 865 5
Alcoholism 1099 6 914 5
Types of H2RA used
d
Cimetidine 13826 79
Ranitidine 1684 10
Nizatidine 1029 6
Famotidine 15 0
Ranitidine bismuth citrate 5 0
Mixed use 919 5
Types of PPI used
d
Omeprazole 9263 49
Lanzoprazole 3366 18
Esomeprazole 1929 10
Pantoprazole 1093 6
Rabeprazole 215 1
Mixed use 2924 16
Abbreviations: COPD¼chronic obstructive pulmonary disorder; H2RA¼histamine-
2-antagonist; NSAID¼non-steroidal anti-inflammatory drug; PPI¼proton pump
inhibitor. North Jutland County, Denmark (1990–2003).
aSimultaneous prescription
for any two of three antibiotics: amoxicillin, clarithromycin and metronidazole.
bX1
year before censoring events.
cFrom public prescription and discharge registries.
dFrom the first two prescriptions registered.
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pared with non-users of acid-suppressing drugs (data not shown).
The vast majority of the gastric cancers were adenocarcinomas.
Two gastric tumours observed in PPI users were classified as
carcinoids and both were diagnosed within 1 year of the second
PPI-prescription. No carcinoids were observed among H2RA users.
DISCUSSION
In this prospective, population-based cohort study risk estimates
for gastric cancer among users of either PPI or H2RA were close to
unity after incorporating a 1-year lag time. This is in contrast to a
substantially increased overall incidence of gastric cancer among
users of either PPI or H2RA in analysis without lag time. In the
lagged analyses, we observed increased risk estimates among PPI
users with most prescriptions or longest follow-up when compared
with non-users of acid-suppressive drugs or with H2RA users.
Earlier studies of acid-suppressive drugs and gastric cancer
have also reported an increased risk of gastric cancer associated
with PPI use beyond the first year of treatment (Bateman et al,
2003; Garcia Rodriguez et al, 2006). In a cohort of 18000 British
PPI users, a sevenfold increased risk of death from gastric cancer
was found, which disappeared by the fourth year of follow-up,
indicating that this was because of confounding by indication
rather than a causal relationship with PPI use (Bateman et al,
2003). A recent case–control study, based on the General Practice
Research Database, reported that current PPI users with more than
3 years of use experienced a threefold increased risk (OR 3.0, 95%
CI: 1.0–9.0) of non-cardia gastric cancer, whereas current long-
term users of H2RA had no excess risk (OR 0.9, 95% CI: 0.5–1.8)
(Garcia Rodriguez et al, 2006). The excess risk among PPI users
was largely restricted to patients with ulcer indications. The
authors argued that as gastric ulcers are associated with gastric
neoplasia it was not possible to determine if the excess cancer
risk was attributable to the underlying ulcer or to PPI use (Garcia
Rodriguez et al, 2006; McColl, 2006).
Our finding of excess gastric cancer among with the greatest
number of PPI prescriptions or longest follow-up, even after taking
a 1-year lag time into account, would be compatible with a causal
association with gastric cancer. However, a more likely explanation
is confounding by indication, with H. pylori infection acting as the
underlying risk factor associated with both gastric ulcer – and thus
PPI treatment – and gastric cancer (13% of PPI users vs 4% H2RA
users had undergone eradication therapy). Our observation that
the excess risk among PPI users was largely confined to individuals
with an earlier history of H. pylori eradication (IRR¼3.3) supports
this interpretation. On the other hand, increased risk estimates for
gastric cancer with extended follow-up were also seen when
compared with H2RA users who are likely to be more similar to
PPI users in terms of underlying indications and comorbid
conditions, although these estimates were based on small numbers.
Moreover, as PPIs are more potent than H2RAs, there may be
potential for confounding by severity of disease in the comparison
of PPI and H2RA use.
Our study had the advantage of collecting information from
population-based databases with virtually complete data on drug
prescriptions and cancer diagnoses, thus minimising the possibi-
lity of selection and information biases. Another strength was our
ability to apply a new-user design (Ray, 2003) with limited loss of
eligible PPI users, as marketing of PPIs first began in 1989 and
PPIs were only available on prescription during the study period.
H2RA was available over-the-counter throughout the study period,
however, individuals obtaining H2RA by prescription presumably
included most long-term users and likely had an indication pattern
similar to that of PPI users. Finally, our exposure definition of two
or more prescriptions for either PPI or H2RA makes non-
compliance unlikely.
The main limitations were the small number of long-term users
of PPI, our inability to address subtypes of gastric cancer, and our
inability to adjust for indication of use of PPI and H2RA. We were
able to evaluate the influence of H. pylori infection, but only for
those study subjects who underwent eradication therapy, thus
residual confounding by untreated H. pylori infection may have
influenced our results. We adjusted the risk estimates for NSAID
use, which has been associated with a reduced risk of gastric
cancer (Wang et al, 2003), but we were not able to adjust for
dietary factors, and only proxy measures for tobacco and alcohol
use. Finally, our study had relatively low-statistical precision.
The increased incidence of gastric cancer associated with PPI
use observed in this and earlier studies is likely to result from
confounding by indication; nevertheless, we cannot rule out the
possibility of a causal association between long-term PPI use and
risk of gastric cancer. Larger studies of long-term PPI use would be
required to clarify this issue.
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